Diamyd’s GABA-Based Remygen® Unsuccessful in Phase 1 Clinical Trial

This clinical trial tested whether long-term daily treatment with Remygen®, an oral drug developed by Diamyd Medical, could help restore insulin production in adults with longstanding type 1 diabetes (T1D). The active component of Remygen® is GABA (gamma-aminobutyric acid), a compound that in earlier experimental studies appeared to support the regeneration of insulin-producing beta cells, improve…